LAPLACE-TIMI 57 assessed whether 12 weeks of therapy with a novel injectable monoclonal antibody against PCSK9, given on a background of statin therapy, will be safe and to what degree it will reduce LDL-cholesterol in hypercholesterolemic subjects. MAIN RESULTS: Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination … Continue reading LAPLACE-TIMI 57